Cells of origin in cancer

By Jane E. Visvader. Nature, 2011

1,493 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Distinct EMT programs control normal mammary stem cells and tumour-initiating cells (2015, neutral): “2c, e), echoing the proposal that in human breast carcinomas, aggressive cancer cells exhibiting basal features can actually arise from luminal precursors 13-17 .”
Cholangiocarcinoma 2020: the next horizon in mechanisms and management (2020, positive): “Growing evidence demonstrates that distinct cells of origin within an organ can give rise to different subtypes of cancer, typically tissue-specific stem and progenitor cells 59–62 .”
Mosaic Analysis with Double Markers (MADM) Reveals Tumor Cell-of-Origin in Glioma (2011, neutral): “An alternative approach is to analyze aberrant growth in all cell lineages derived from initial mutant cells during pretransforming stages (Visvader, 2011), which is now possible with MADM-based cancer models.”
Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor (2012, background): “Both clonal evolution and cancer stem cell models suggest that drug resistance and tumor relapse are the result of intratumoral heterogeneity and subpopulation diversity of cancer cells (Marusyk and Polyak, 2010; Visvader, 2011).”
Targeted drug delivery to tumors: Myths, reality and possibility (2011, neutral): “As stem cells for various tissue cell types do not always reside in that tissue or organ [8], the strategies to effectively target drugs to both tumor and non-tumor sites may be what is required.”